Dezima's CETP inhibitor could be 'cheaper, oral' alternative to PCSK9s
This article was originally published in Scrip
Executive Summary
Dezima Pharma has published highly positive results of the Phase IIb TULIP study with its CETP inhibitor, TA-8995, in the Lancet. The potency demonstrated by Dezima's product suggests it has potential as a more cost-effective option for lowering cholesterol than the PCSK9 inhibitor approach.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.